Improving Medical and Cosmetic Outcomes in Actinic Keratoses

A supplement to Skin & Allergy News supported by a restricted educational grant from 3M Pharmaceuticals. Highlights of presentations developed from a roundtable discussion that took place in San Francisco, CA on September 5, 2003.
Skin & Allergy News certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

•Topics
•Faculty
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 16.

Topics

• Consequences of Photodamage: Actinic Keratosis Etiopathogenesis
• Lesion-Targeted Versus Field Therapy for Actinic Keratoses
• Actinic Keratosis in the Immunocompromised Host
• Optimizing Patient Compliance and Comfort with Immune Response Modifier Therapy
• Prevention and Treatment of Sun Damage: Preserving Cosmetic Integrity

Faculty

Howard I. Maibach, MD
Chair
Professor of Dermatology
Department of Dermatology
University of California
San Francisco
Nothing to disclose.

Anthony A. Gaspari, MD
Professor of Dermatology
Department of Dermatology
University of Maryland School of Medicine
Baltimore
Received a research grant from and is on the Medical Advisory Board of 3M Pharmaceuticals. Discusses the investigational use of imiquimod for the treatment of actinic keratosis and basal cell carcinoma.

James M. Spencer, MD, MS
Vice Chairman and Associate Professor
Department of Dermatology
Mount Sinai Medical Center
New York
Clinical Grants: 3M Pharmaceuticals and ICN Pharmaceuticals, Inc. Consultant to and has a financial interest in PhotoMedex. He discusses the investigational use of imiquimod for the treatment of actinic keratosis.

Richard Allen Johnson, MD
Instructor in Dermatology
Harvard Medical School
Clinical Associate in Dermatology
Massachusetts General Hospital
Boston
He discusses the investigational use of acitretin, adapalense, imiquimod, tazarotene, and tretinoin for the prevention of actinic keratosis and squamous cell carcinoma in organ transplant recipients. He also discusses the investigational use of isotretinoin for the treatment of xeroderma pigmentosum.

Phoebe Rich, MD
Clinical Professor of Dermatology
Oregon Health Sciences University
Private Dermatology Practice
Portland
Clinical Grants and Consultant: 3M Pharmaceuticals. She discusses the investigational use of imiquimod for the treatment of actinic keratosis.

Leslie S. Baumann, MD
Director, Division of Cosmetic Dermatology
Associate Professor
Department of Dermatology
University of Miami
Miami
Discusses the investigational use of imiquimod for the treatment of actinic keratosis.

Target Audience

This activity has been developed for dermatologists and other health care professionals who are involved in the diagnosis, treatment and long-term management of patients with actinic keratosis (AKs).

Educational Needs

Long-term ultraviolet (UV) radiation from the sun and tanning salons is now known to result in photodamage to the skin that has both medical and cosmetic consequences. New findings from basic scientific research have provided information that is crucial to the understanding of the process of photodamage and photoaging on biochemical and genetic levels. In addition, clinical studies have explored the efficacy and safety of a range of treatments for actinic keratoses. Dermatologists must be kept up-to-date on these findings to be able to advise patients about the latest information on prevention of photodamage and photoaging and to guide them through informed choices about treatment.

Learning Objectives

By reading and studying this supplement, participants should be able to:

• Discuss the most recent findings in basic scientific research that explain how ultraviolet radiation affects skin cells to produce actinic keratoses and manifestations of aging, such as wrinkling.

• Summarize the modalities currently available for the treatment of AKs, including immune response modifier therapy, and list the major advantages and disadvantages of each.

• Describe what is currently known about actinic keratoses and invasive squamous cell carcinoma in immunocompromised patients.

• Explain the newest findings concerning the pathways of photoaging and the methods for blocking these pathways.

CME Recognition

Skin & Allergy News certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award. This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.

Term of approval: January 2004-December 2004.

Copyright © 2004 by International Medical News Group

---